AZ and MRC Tech form respiratory disease pact
Medical research charity MRC Technology and AstraZeneca are partnering to launch an initiative to find new epigenetic drug targets in respiratory disease.
Read More
Tag: epigenetic targets
- FDA approves new high dose Spinraza regimen for SMA
- Viridian reports positive results from elegrobart phase 3 trial
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
